FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196397673> ?p ?o ?g. }

• W3196397673 abstract "Lack of biomarkers and in vitro models has contributed to inadequate understanding of the mechanisms underlying the inferior clinical response to immune checkpoint inhibitors (ICIs) in patients with oncogene-driven non-small cell lung cancer (NSCLC).The effect of small molecule tyrosine kinase inhibitors (TKIs) on peripheral blood mononuclear cells (PBMCs) in 34 patients with oncogene-driven NSCLC (cohort A) was compared with those from 35 NSCLC patients without oncogene-driven mutations received ICI (cohort B) or from 22 treatment-naïve NSCLC patients (cohort C). Data for each blood biomarker were summarized by mean and standard deviation and compared by Wilcoxon rank sum tests or Kruskal-Wallis tests with significance at 2-sided p value < 0.05. Co-culture of PBMCs and pleural effusion-derived tumor cells from individual patients with oncogene-driven NSCLC was used to determine the in vitro cytotoxicity of TKI and ICI.Except for low CD3% in cohort A, there were no significant differences in other 12 blood biomarkers among the 3 cohorts at baseline. TKI treatment in cohort A was associated with significant increase in CD3% and decrease in total and absolute neutrophils (p < 0.05). In cohort B, patients with good clinical response to ICI treatment (N = 18) had significant increases in absolute lymphocyte counts (ALCs), CD4 and/or CD8 cell counts. Conversely, those patients with poor clinical response to ICI (N = 17) had significant decreases in these cell counts. Of the 27 patients with pre- and post-treatment blood samples in cohort A, 11 had poor clinical response to TKIs and decreased lymphocyte counts. Of the remaining 16 patients who had good clinical response to TKI therapy, 10 (62.5%) patients had decreased, and 6 (37.5%) patients had increased lymphocyte counts. Multicolor immunophenotyping of PBMCs revealed ICI treatment activated additional immune cell types that need further validation. We confirmed that TKI treatment could either antagonize or enhance the effect of ICIs in the co-culture assay using patient's tumor cells and PBMCs.To the best of our knowledge, this is the first study showing that TKIs can have various effects on blood immune cells, which may affect their response to ICIs. Further validation of the blood biomarker and in vitro assay is warranted." @default.
• W3196397673 created "2021-09-13" @default.
• W3196397673 creator A5006450872 @default.
• W3196397673 creator A5036031389 @default.
• W3196397673 creator A5036407587 @default.
• W3196397673 creator A5049317673 @default.
• W3196397673 creator A5049789886 @default.
• W3196397673 creator A5071181878 @default.
• W3196397673 creator A5087045498 @default.
• W3196397673 creator A5089304233 @default.
• W3196397673 date "2021-09-06" @default.
• W3196397673 modified "2023-09-23" @default.
• W3196397673 title "Small molecule tyrosine kinase inhibitors modulated blood immune cell counts in patients with oncogene-driven NSCLC" @default.
• W3196397673 cites W1539059550 @default.
• W3196397673 cites W1757492577 @default.
• W3196397673 cites W1982344314 @default.
• W3196397673 cites W2019607817 @default.
• W3196397673 cites W2088270805 @default.
• W3196397673 cites W2096198395 @default.
• W3196397673 cites W2104830962 @default.
• W3196397673 cites W2138297714 @default.
• W3196397673 cites W2139758621 @default.
• W3196397673 cites W2147592245 @default.
• W3196397673 cites W2148237316 @default.
• W3196397673 cites W2158333823 @default.
• W3196397673 cites W2171139285 @default.
• W3196397673 cites W2400328547 @default.
• W3196397673 cites W2400514548 @default.
• W3196397673 cites W2528186273 @default.
• W3196397673 cites W2563390944 @default.
• W3196397673 cites W2567636536 @default.
• W3196397673 cites W2575258963 @default.
• W3196397673 cites W2601207912 @default.
• W3196397673 cites W2601621622 @default.
• W3196397673 cites W2610816290 @default.
• W3196397673 cites W2613260339 @default.
• W3196397673 cites W2615735040 @default.
• W3196397673 cites W2624310346 @default.
• W3196397673 cites W2737044461 @default.
• W3196397673 cites W2760639821 @default.
• W3196397673 cites W2770828094 @default.
• W3196397673 cites W2777461561 @default.
• W3196397673 cites W2783897381 @default.
• W3196397673 cites W2786511378 @default.
• W3196397673 cites W2794965437 @default.
• W3196397673 cites W2795845948 @default.
• W3196397673 cites W2802193277 @default.
• W3196397673 cites W2803397860 @default.
• W3196397673 cites W2806325305 @default.
• W3196397673 cites W2808178081 @default.
• W3196397673 cites W2889026937 @default.
• W3196397673 cites W2889653218 @default.
• W3196397673 cites W2891951654 @default.
• W3196397673 cites W2894476389 @default.
• W3196397673 cites W2899411597 @default.
• W3196397673 cites W2902185751 @default.
• W3196397673 cites W2924289105 @default.
• W3196397673 cites W2947849947 @default.
• W3196397673 cites W2953307605 @default.
• W3196397673 cites W2953693252 @default.
• W3196397673 cites W2959572057 @default.
• W3196397673 cites W2972582992 @default.
• W3196397673 cites W2978677918 @default.
• W3196397673 cites W2990041408 @default.
• W3196397673 cites W3001408868 @default.
• W3196397673 cites W3013584950 @default.
• W3196397673 cites W3028523516 @default.
• W3196397673 cites W3081278682 @default.
• W3196397673 cites W3082015854 @default.
• W3196397673 cites W3087210493 @default.
• W3196397673 cites W3093770256 @default.
• W3196397673 cites W3108819942 @default.
• W3196397673 cites W3110810484 @default.
• W3196397673 cites W3112757188 @default.
• W3196397673 cites W3120541246 @default.
• W3196397673 cites W3123313279 @default.
• W3196397673 cites W3127505349 @default.
• W3196397673 cites W3131416308 @default.
• W3196397673 doi "https://doi.org/10.1186/s40364-021-00324-6" @default.
• W3196397673 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8419812" @default.
• W3196397673 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34488906" @default.
• W3196397673 hasPublicationYear "2021" @default.
• W3196397673 type Work @default.
• W3196397673 sameAs 3196397673 @default.
• W3196397673 citedByCount "3" @default.
• W3196397673 countsByYear W31963976732022 @default.
• W3196397673 countsByYear W31963976732023 @default.
• W3196397673 crossrefType "journal-article" @default.
• W3196397673 hasAuthorship W3196397673A5006450872 @default.
• W3196397673 hasAuthorship W3196397673A5036031389 @default.
• W3196397673 hasAuthorship W3196397673A5036407587 @default.
• W3196397673 hasAuthorship W3196397673A5049317673 @default.
• W3196397673 hasAuthorship W3196397673A5049789886 @default.
• W3196397673 hasAuthorship W3196397673A5071181878 @default.
• W3196397673 hasAuthorship W3196397673A5087045498 @default.
• W3196397673 hasAuthorship W3196397673A5089304233 @default.
• W3196397673 hasBestOaLocation W31963976731 @default.
• W3196397673 hasConcept C121608353 @default.
• W3196397673 hasConcept C126322002 @default.
• W3196397673 hasConcept C137061746 @default.

• next